Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
Third Harmonic Bio (Nasdaq: THRD) has announced its participation in the 7th Annual Evercore HealthCONx Conference. Chris Murphy, Chief Financial and Business Officer, will engage in a fireside chat on December 4, 2024, at 9:35 a.m. The company, which focuses on developing treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide a live audio webcast accessible through their website's Investors & Media section. The replay will remain available for 90 days after the event.
Third Harmonic Bio (Nasdaq: THRD) ha annunciato la sua partecipazione alla 7ª Conferenza Annuale Evercore HealthCONx. Chris Murphy, Direttore Finanziario e Commerciale, parteciperà a una chiacchierata informale il 4 dicembre 2024 alle 9:35. L'azienda, che si concentra sullo sviluppo di trattamenti per malattie infiammatorie dermiche, respiratorie e gastroenterologiche, offrirà una trasmissione audio in diretta accessibile attraverso la sezione Investitori e Media del loro sito web. La replica rimarrà disponibile per 90 giorni dopo l'evento.
Third Harmonic Bio (Nasdaq: THRD) ha anunciado su participación en la 7ª Conferencia Anual Evercore HealthCONx. Chris Murphy, Director Financiero y de Negocios, participará en una charla junto a la chimenea el 4 de diciembre de 2024 a las 9:35 a.m. La empresa, que se centra en el desarrollo de tratamientos para enfermedades inflamatorias dérmicas, respiratorias y gastrointestinales, ofrecerá una transmisión de audio en vivo accesible a través de la sección de Inversores y Medios de su sitio web. La repetición estará disponible durante 90 días después del evento.
Third Harmonic Bio (Nasdaq: THRD)는 제7회 연례 Evercore HealthCONx 컨퍼런스에 참여할 것이라고 발표했습니다. Chris Murphy 최고 재무 및 비즈니스 책임자는 2024년 12월 4일 오전 9시 35분에 난상 토론에 참여할 예정입니다. 피부, 호흡기 및 위장 염증 질환에 대한 치료 개발에 집중하는 이 회사는 투자자 및 미디어 섹션을 통해 웹사이트에서 액세스할 수 있는 실시간 오디오 웹캐스트를 제공할 것입니다. 이벤트 후 90일 동안 다시 시청할 수 있습니다.
Third Harmonic Bio (Nasdaq: THRD) a annoncé sa participation à la 7e Conférence Annuelle Evercore HealthCONx. Chris Murphy, Responsable Financier et Commercial, participera à une discussion informelle le 4 décembre 2024 à 9h35. L'entreprise, qui se concentre sur le développement de traitements pour les maladies inflammatoires dermatologiques, respiratoires et gastro-intestinales, proposera un webinaire audio en direct accessible via la section Investisseurs et Médias de son site web. La rediffusion sera disponible pendant 90 jours après l'événement.
Third Harmonic Bio (Nasdaq: THRD) hat seine Teilnahme an der 7. jährlichen Evercore HealthCONx-Konferenz angekündigt. Chris Murphy, Chief Financial and Business Officer, wird am 4. Dezember 2024 um 9:35 Uhr an einem Gespräch teilnehmen. Das Unternehmen, das sich auf die Entwicklung von Behandlungen für dermale, respiratorische und gastrointestinal entzündliche Erkrankungen konzentriert, wird eine Live-Audiosendung anbieten, die über den Bereich Investoren und Medien auf ihrer Website zugänglich ist. Die Wiederholung wird 90 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024, at 9:35 a.m.
A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event.
About Third Harmonic Bio, Inc.
Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral, small molecule inhibitor that is currently in a Phase 1 clinical trial. For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.
Investor and Media Contact:
Lori Murray
lori.murray@thirdharmonicbio.com
FAQ
When is Third Harmonic Bio (THRD) presenting at the Evercore HealthCONx Conference 2024?
How long will the Third Harmonic Bio (THRD) Evercore Conference webcast be available?
What therapeutic areas does Third Harmonic Bio (THRD) focus on?
Who will represent Third Harmonic Bio (THRD) at the 2024 Evercore Conference?
